An observational study in Parkinsonian Disorders, Parkinson Disease and Lewy Body Disease, sponsored by Dorian Technologies S.r.l.. Recruiting at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Dorian Technologies S.r.l. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Parkinsonian Disorders with a site in Italy — 5 open to participants now, 5 under way, none of them phase 3. Parkinsonian Disorders · Italy.
Among the 23 studies in Parkinsonian Disorders with a site in Italy, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 23rd registered.
218 studies on the registry are indexed under Parkinsonian Disorders; 63 are open to participants now.
Browse Parkinsonian Disorders studies →5 of the 23 studies in Parkinsonian Disorders with a site in Italy are open now. Recruiting first, the newest first:
Fondazione Don Carlo Gnocchi ETS · Sites in Italy
Ages 45+
Azienda USL Reggio Emilia - IRCCS · Sites in Italy
Ages 18+
Fondazione Don Carlo Gnocchi Onlus · Sites in Italy
Ages 60–85
IRCCS San Raffaele Roma · Sites in Italy
Ages 35–80 · Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 45 Parkinsonian Disorders studies recruiting now, 18 (40%) set no upper age limit and 9 (20%) stop at 75 or younger; 4 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is below the median of 150 across 74 observational studies indexed under Parkinsonian Disorders.
Median enrollment 172 across the 16 interventional studies, 158 across the 6 observational. Of the 15 that completed or were terminated, 5 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 23 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Dorian Technologies S.r.l. as lead sponsor.
Dorian Technologies S.r.l. has 1 study filed under Parkinsonian Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies in Parkinsonian Disorders with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07943702Dorian Technologies S.r.l.Correlation Between Visual Reading and DOlab Software Quantitative Analysis of DaT-SPECT Images | 2027-01 |
| NCT06869135Fondazione Don Carlo Gnocchi ETSSaliva and Extracellular Vesicles for Neurodegenerative Diseases | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Parkinsonian Disorders with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to find out whether the quantitative results of DOlab software (DaT-SPECT workflow) agree with the visual reading of brain scans performed by nuclear medicine physicians. The scans are 123I-ioflupane DaT-SPECT images of adults who were evaluated for dopamine transporter dysfunction, a condition seen in Parkinson's disease, other parkinsonian syndromes and dementia with Lewy bodies.
The main questions it aims to answer are:
The study uses existing scans of 120 patients collected between January 2015 and May 2025 at two Italian hospitals. No new tests or treatments are given to participants, and the software results are not used for their clinical care.
Dopamine transporter (DaT) SPECT with 123I-ioflupane is widely used to support the diagnosis of neurological disorders associated with nigrostriatal dopaminergic degeneration. Visual reading by trained physicians is the clinical standard, and semi-quantitative analysis is recommended by the EANM/SNMMI guidelines as an objective complement, especially in borderline cases.
DOlab software - DaT-SPECT workflow (Dorian Technologies; investigational, not CE-marked, class IIa) iteratively maps each scan to MNI space with adaptive volumes of interest for the right and left caudate, anterior putamen and posterior putamen, plus an occipital reference region. It computes four metrics: striatal binding ratio (SBR), Southampton SBR, Basal Ganglia V3 and Volume Fraction. The results are compared with a normative database derived from the Parkinson's Progression Markers Initiative (PPMI) and reported as z-scores.
This is a blinded, multicenter, retrospective investigation at two Italian sites. At each site, an independent reader selects 15 consecutive scans for each visual grade (0, 1, 2, 3), for a total of 120 scans. The images are pseudonymized and uploaded to a shared repository.
Phase 1: four independent readers (two per site), blinded to all clinical information except sex and age, visually score the randomized images (0-3) for the caudate, anterior putamen and posterior putamen of each hemisphere. In parallel, the software analyzes the same images, and the visual scores are correlated with the software metrics.
Phase 2: the images are re-randomized and re-coded, and the same readers perform a semi-quantitative assessment supported by the software report. Classifications from the two phases are then compared. Finally, the readers complete the System Usability Scale (SUS).
Sample size: 85 subjects are needed to detect a correlation of 0.30 (two-sided alpha 0.05, power 80%). 120 subjects are planned to allow for non-evaluable images.
Adults referred for evaluation of nigrostriatal dopaminergic dysfunction who underwent 123I-ioflupane DaT-SPECT between January 2015 and May 2025 at Santo Stefano Hospital (Prato) or the University Hospital of Padua, Italy. At each center, 15 consecutive scans per visual grade (negative, mild, moderate and marked abnormality) are selected retrospectively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults referred for evaluation of nigrostriatal dopaminergic dysfunction at the two participating centers between January 2015 and May 2025, whose existing 123I-ioflupane DaT-SPECT scans were selected retrospectively (30 per visual grade 0-3, 15 per grade per center). Each scan is read visually by four blinded readers, analyzed by DOlab software, and then re-read with the software report.
Device: DOlab software - DaT-SPECT workflow · Diagnostic Test: Visual interpretation (comparator)
Investigational software (not CE-marked, class IIa) that automatically quantifies striatal 123I-ioflupane binding using four metrics (SBR, Southampton SBR, Basal Ganglia V3, Volume Fraction) and compares them with a PPMI-based normative database. It is applied retrospectively to existing images, and its output is not used for patient care.
Visual reading of the same 123I-ioflupane images by blinded nuclear medicine physicians, scored 0-3 for the caudate, anterior putamen and posterior putamen of each hemisphere, according to the EANM/SNMMI guidelines.
Correlation between visual score and DOlab quantitative metrics
Pearson correlation coefficient (with 95% CI) between the readers' visual score (ordinal 0-3; 0 = normal, 3 = marked abnormality) and each continuous metric produced by DOlab software (SBR, Southampton SBR, Basal Ganglia V3, Volume Fraction) for the caudate, anterior putamen and posterior putamen of each hemisphere. If the Pearson assumptions are not met, the Spearman rank correlation is reported.
Time frame: Phase 1 reading session, within 4 months of study start
Agreement between visual and software-supported semi-quantitative classification
Cohen's kappa coefficient between the classifications given by the same readers with visual reading alone (Phase 1) and with the DOlab software report (Phase 2).
Time frame: Phase 2 reading session, within 4 months of study start
Number of scans reclassified with software support
Number and percentage of scans whose classification changes between visual reading alone and software-supported reading (e.g., borderline to abnormal), tested with McNemar's test for paired proportions.
Time frame: Phase 2 reading session, within 4 months of study start
Software usability (System Usability Scale)
SUS questionnaire completed by the 4 readers: 10 items on a 5-point scale. SUS total score from 0 to 100, where higher scores indicate better perceived usability; item responses are also reported as median and IQR.
Time frame: After the Phase 2 reading session, within 4 months of study start
Plan to share: No — Individual participant data and images will not be shared, because the clinical investigation plan restricts data use to the sponsor and investigators and the dataset includes pseudonymized imaging data of patients who could not all be reconsented. Aggregate results will be published.
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Jan 2027, 3 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.